SCLX vs. PBYI, GALT, IVA, CAPR, INGN, VERU, PROF, OGI, ELEV, and GNFT
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Puma Biotechnology (PBYI), Galectin Therapeutics (GALT), Inventiva (IVA), Capricor Therapeutics (CAPR), Inogen (INGN), Veru (VERU), Profound Medical (PROF), Organigram (OGI), Elevation Oncology (ELEV), and Genfit (GNFT). These companies are all part of the "medical" sector.
Puma Biotechnology (NASDAQ:PBYI) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of -229.47%. Scilex's return on equity of 35.49% beat Puma Biotechnology's return on equity.
Puma Biotechnology received 532 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 66.54% of users gave Puma Biotechnology an outperform vote.
Puma Biotechnology has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology currently has a consensus target price of $7.00, indicating a potential upside of 72.41%. Scilex has a consensus target price of $5.50, indicating a potential upside of 395.50%. Given Puma Biotechnology's higher possible upside, analysts plainly believe Scilex is more favorable than Puma Biotechnology.
In the previous week, Scilex had 13 more articles in the media than Puma Biotechnology. MarketBeat recorded 18 mentions for Scilex and 5 mentions for Puma Biotechnology. Scilex's average media sentiment score of 0.50 beat Puma Biotechnology's score of 0.06 indicating that Puma Biotechnology is being referred to more favorably in the media.
Puma Biotechnology has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Scilex has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by insiders. Comparatively, 8.7% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Puma Biotechnology beats Scilex on 11 of the 17 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
